Список литературы

1. Ferrer I, Martinez A, Blanco R, Dalfo E, Carmona M. Neuropathology of sporadic Parkinson disease before the appearance of parkinsonism: preclinical Parkinson disease. J Neural Transm. 2011;118:821-839.

2. Muller B, Larsen JP, Wentzel-Larsen T, Skeie GO, Tysnes OB; Parkwest Study Group. Autonomic and sensory symptoms and signs in inci­dent, untreated Parkinson's disease: frequent but mild. Mov Disord. 2011;26:65-72.

3. Ellis TD, Cavanaugh JT, Earhart GM, et al. Identifying clinical measures that most accurately reflect the progression of disability in Parkinson disease. Parkinsonism Relat Disord. 2016;25:65-71.

4. Stocchi F, Jenner P, Obeso JA. When do levodopa motor fluctuations first appear in Parkinson's disease? Eur Neurol. 2010;63:257-266.

5. Olanow CW, Watts RL, Koller WC. An algorithm (decision tree) for the management of Parkinson's disease (2001): treatment guidelines. Neurology. 2001;56(11 Suppl 5):S1-S88.

6. Miyasaki JM, Martin W, Suchowersky O, Weiner WJ, Lang AE. Practice parameter: initiation of treatment for Parkinson's dis­ease: an evidence-based review. Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology. 2002;58:11-17.

7. Pahwa R, Factor SA, Lyons KE, et al. Practice parameter: treat­ment of Parkinson disease with motor fluctuations and dyskine­sia (an evidence-based review). Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology. 2006;66:983-995.

8. National Collaborating Centre for Chronic Conditions (UK). Parkinson's Disease: National Clinical Guideline for Diagnosis and Management in Primary and Secondary Care. London: Royal College of Physicians (UK); 2006.

9. Oertel WH, Berardelli A, Bloem BR, et al. Chapter 14: early (uncompli­cated) Parkinson's disease. In: Gilhus NE, Barnes MR, Brainin M, eds. European Handbook of Neurological Management: Vol 1. 2nd edition. Chichester: Blackwell; 2010:217-236.

10. Oertel WH, Berardelli A, Bloem BR, et al. Chapter 15: late (compli­cated) Parkinson's disease. In: Gilhus NE, Barnes MR, Brainin M, eds. European Handbook of Neurological Management. Vol 1, 2nd edition. Chichester: Blackwell; 2010:237-267.

11. Ferreira JJ, Katzenschlager R, Bloem BR, et al. Summary of the rec­ommendations of the EFNS/MDS-ES review on therapeutic manage­ment of Parkinson's disease. Eur J Neurol. 2013;20:5-15.

12. Connolly BS, Lang AE. Pharmacological treatment of Parkinson dis­ease: a review. JAMA. 2014;311:1670-1683.

13. Grimes D, Gordon J, Snelgrove B, et al. Canadian Neurological Sciences Federation. Canadian guidelines on Parkinson's disease. Can J Neurol Sci. 2012;39(4 Suppl 4):S1-S30.

14. DANMODIS. Parkinsons sygdom. Klinisk vejledning. 2nd Edition, 2011. http://neuro.dk/wordpress/wp-content/uploads/2012/09/Parkinsons_sygdom_Klinisk_Vejledning_2011.pdf. Accessed

December 7, 2016.

15. SWEMODIS. Svenska riktlinjer for utredning och behandling av Parkinsons sjukdom. 7th Edition, 2014. http://www.swemodis.se/ images/Dokument/Terapird%20Parkinsons%20sjukdom%20ver- sion%207%202014.pdf. Accessed December 7 2016.

16. Referansegruppen for Nasjonal kompetansetjeneste for bevegelses- forstyrrelser. Revidert terapianbefaling ved Parkinsons sykdom. 6th Edition, 2014. https://helse-stavanger.no/seksjon/NKB/Documents/ Nyhetsbulletin/Nyhetsbulletin%202014%20-%20nr.%202.pdf. Accessed December 7, 2016.

17. Reichmann H. Modern treatment in Parkinson's disease, a personal approach. J Neural Transm. 2016;123:73-80.

18. Deutsche Gesellschaft fur Neurologie. Idiopathisches Parkinson- Syndrom.Leitlinienfur Diagnostik undTherapiein der Neurologie. 2016. www.dgn.org/images/red_leitlinien/LL_2016/PDFs_Download/ 030010_LL_langfassung_ips_2016.pdf. Accessed October 17, 2016.

19. Socialstyrelsen. Nationella riktlinjer for vard vid multipel skleros

och Parkinsons sjukdom. Stod for styrning och ledning. Stockholm, 2016. http://www.socialstyrelsen.se/Lists/Artikelkatalog/

Attachments/20392/2016-12-1.pdf. Accessed December 6, 2016.

20. Chaudhuri KR, Odin P, Antonini A, Martinez-Martin P. Parkinson's disease: the non-motor issues. Parkinsonism Relat Disord. 2011;17:717-723.

21. Schrag A, Sauerbier A, Chaudhuri KR. New clinical trials for nonmotor manifestations of Parkinson's disease. Mov Disord. 2015;30:1490-1504.

22. Parkinson Study Group. Effects of tocopherol and deprenyl on the progression of disability in early Parkinson's disease. N Engl J Med. 1993;328:176-183.

23. Larsen JP, Boas J, Erdal JE. Does selegiline modify the progression of early Parkinson's disease? Results from a five-year study. The Norwegian-Danish Study Group. Eur J Neurol. 1999;6:539-547.

24. Palhagen S, Heinonen E, Hagglund J, Kaugesaar T, Maki-Ikola O, Palm R; Swedish Parkinson Study Group. Selegiline slows the progression of the symptoms of Parkinson disease. Neurology. 2006;66:1200-1206.

25. Olanow CW, Rascol O, Hauser R, et al. A double-blind, delayed- start trial of rasagiline in Parkinson's disease. N Engl J Med. 2009;361:1268-1278.

26. Ahlskog JE, Uitti RJ. Rasagiline, Parkinson neuroprotection, and delayed- start trials: still no satisfaction? Neurology. 2010;74:1143-1148.

27. Clarke CE, Patel S, Ives N, Rick C, Wheatley K, Gray R. Should treatment for Parkinson's disease start immediately on diagno­sis or delayed until functional disability develops? Mov Disord. 2011;26:1187-1193.

28. Rascol O, Hauser RA, Stocchi F, et al. Long-term effects of rasagaline and the natural history of treated Parkinson's disease. Mov Disord. 2016;31:1489-1496.

29. Fahn S, Oakes D, Shoulson I, et al. Levodopa and the progression of Parkinson's disease. N Engl J Med. 2004;351:2498-2508.

30. Rascol O, Brooks DJ, Korczyn AD, De Deyn PP, Clarke CE, Lang AE. A five-year study of the incidence of dyskinesia in patients with early Parkinson's disease who were treated with ropinirole or levodopa. N Engl J Med. 2000;342:1484-1491.

31. Holloway RG, Shoulson I, Fahn S, et al. Pramipexole vs levodopa as ini­tial treatment for Parkinson disease: a 4-year randomized controlled trial. Arch Neurol. 2004;61:1044-1053.

32. PD Med Collaborative Group, Gray R, Ives N, et al. Long-term effec­tiveness of dopamine agonists and monoamine oxidase B inhibitors compared with levodopa as initial treatment for Parkinson's disease (PD MED): a large, open-label, pragmatic randomised trial. Lancet. 2014;384:1196-1205.

33. Antonini A, Poewe W. Fibrotic heart-valve reactions to dopamine- agonist treatment in Parkinson's disease. Lancet Neurol. 2007;6:826-829.

34. Weintraub D, Koester J, Potenza MN, et al. Impulse control disorders in Parkinson disease: a cross-sectional study of 3090 patients. Arch Neurol. 2010;67:589-595.

35. Garcia-Ruiz PJ, Martinez Castrillo JC, Alonso-Canovas A, et al. Impulse control disorder in patients with Parkinson's disease under dopamine agonist therapy: a multicentre study. J Neurol Neurosurg Psychiatry. 2014;85:840-844.

36. Erga AH, Alves G, Larsen JP, Tysnes OB, Pedersen KF. Impulsive and compulsive behaviors in Parkinson disease: the Norwegian ParkWest Study. J Parkinsons Dis. 2016. doi: 10.3233/JPD-160977.[Epub ahead of print].

37. Rizos A, Sauerbier A, Antonini A, et al. A European multicentre sur­vey of impulse control behaviours in Parkinson's disease patients treated with short- and long-acting dopamine agonists. Eur J Neurol. 2016;23:1255-1261.

38. Olanow CW, Stern MB, Sethi K. The scientific and clinical basis for the treatment of Parkinson disease (2009). Neurology. 2009;72(21 Suppl 4):S1-S136.

39. Chaudhuri KR, Rizos A, Sethi KD. Motor and nonmotor complications in Parkinson's disease: an argument for continuous drug delivery? J Neural Transm. 2013;120:1305-1320.

40. Sawada H, Oeda T, Kuno S, et al. Amantadine for dyskinesias in Parkinson's disease: a randomized controlled trial. PLoS One. 2010;5:e15298.

41. Ory-Magne F, Corvol JC, Azulay JP, et al. Withdrawing amantadine in dyskinetic patients with Parkinson disease: the AMANDYSK trial. Neurology. 2014;82:300-307.

42. Fabbri M, Rosa MM, Abreu D, Ferreira JJ. Clinical pharmacology review of safinamide for the treatment of Parkinson's disease. Neurodegener Dis Manag. 2015;5:481-496.

43. Deuschl G, Schade-Brittinger C, Krack P, et al. A randomized trial of deep-brain stimulation for Parkinson's disease. N Engl J Med. 2006;355:896-908.

44. Krack P, Batir A, Van Blercom N, et al. Five-year follow-up of bilateral stimulation of the subthalamic nucleus in advanced Parkinson's dis­ease. N Engl J Med. 2003;349:1925-1934.

45. Schupbach WM, Chastan N, Welter ML, et al. Stimulation of the sub­thalamic nucleus in Parkinson's disease: a 5 year follow up. J Neurol Neurosurg Psychiatry. 2005;76:1640-1644.

46. Schuepbach WM, Rau J, Knudsen K, et al. Neurostimulation for Parkinson's disease with early motor complications. N Engl J Med. 2013;368:610-622.

47. Kleiner-Fisman G, Herzog J, Fisman DN, et al. Subthalamic nucleus deep brain stimulation: summary and meta-analysis of outcomes. Mov Disord. 2006;21(Suppl 14):S290-S304.

48. Weaver FM, Follett K, Stern M, et al. Bilateral deep brain stimulation vs best medical therapy for patients with advanced Parkinson disease: a randomized controlled trial. JAMA. 2009;301:63-73.

49. Toft M, Dietrichs E. Medication costs following subthalamic nu­cleus deep brain stimulation for Parkinson's disease. Mov Disord. 2014;29:275-276.

50. Odekerken VJ, Boel JA, Schmand BA, et al. GPi vs STN deep brain stimulation for Parkinson disease: three-year follow-up. Neurology. 2016;86:755-761.

51. Boel JA, Odekerken VJ, Geurtsen GJ, et al. Psychiatric and social out­come after deep brain stimulation for advanced Parkinson's disease. Mov Disord. 2016;31:409-413.

52. Bjerknes S, Skogseid IM, S^hle T, Dietrichs E, Toft M. Surgical site infections after deep brain stimulation surgery: frequency, characteristics and management in a 10-year period. PLoS One. 2014;9:e105288.

53. Toft M, Lilleeng B, Ramm-Pettersen J, et al. Long-term efficacy and mortality in Parkinson's disease patients treated with subthalamic stimulation. Mov Disord. 2011;26:1931-1934.

54. Odin P, Ray Chaudhuri K, Slevin JT, et al. Collective physician per­spectives on non-oral medication approaches for the management of clinically relevant unresolved issues in Parkinson's disease: consensus from an international survey and discussion program. Parkinsonism Relat Disord. 2015;21:1133-1144.

55. Soulas T, Gurruchaga JM, Palfi S, Cesaro P, Nguyen JP, Fenelon G. Attempted and completed suicides after subthalamic nucleus stimulation for Parkinson's disease. J Neurol Neurosurg Psychiatry. 2008;79:952-954.

56. Weintraub D, Duda JE, Carlson K, et al. Suicide ideation and be­haviours after STN and GPi DBS surgery for Parkinson's disease: re­sults from a randomised, controlled trial. J Neurol Neurosurg Psychiatry. 2013;84:1113-1118.

57. Temel Y, Kessels A, Tan S, Topdag A, Boon P, Visser-Vandewalle V. Behavioural changes after bilateral subthalamic stimulation in ad­vanced Parkinson disease: a systematic review. Parkinsonism Relat Disord. 2006;12:265-272.

58. Xie Y, Meng X, Xiao J, Zhang J, Zhang J. Cognitive changes following bilateral deep brain stimulation of subthalamic nucleus in Parkinson's disease: a meta-analysis. Biomed Res Int. 2016;2016:3596415.

59. Pham U, Solbakk AK, Skogseid IM, et al. Personality changes after deep brain stimulation in Parkinson's disease. Parkinsons Dis. 2015;2015:490507.

60. Nyholm D, Nilsson Remahl AI, Dizdar N, et al. Duodenal levodopa infusion monotherapy vs oral polypharmacy in advanced Parkinson disease. Neurology. 2005;64:216-223.

61. Nyholm D, Klangemo K, Johansson A. Levodopa/carbidopa intestinal gel infusion long-term therapy in advanced Parkinson's disease. Eur J Neurol. 2012;19:1079-1085.

62. Olanow CW, Kieburtz K, Odin P, et al. Continuous intrajejunal infu­sion of levodopa-carbidopa intestinal gel for patients with advanced Parkinson's disease: a randomised, controlled, double-blind, double­dummy study. Lancet Neurol. 2014;13:141-149.

63. Fernandez HH, Standaert DG, Hauser RA, et al. Levodopa-carbidopa intestinal gel in advanced Parkinson's disease: final 12-month, open- label results. Mov Disord. 2015;30:500-509.

64. Buongiorno M, Antonelli F, Camara A, et al. Long-term response to continuous duodenal infusion of levodopa/carbidopa gel in patients with advanced Parkinson disease: the Barcelona registry. Parkinsonism Relat Disord. 2015;21:871-876.

65. Antonini A, Fung VS, Boyd JT, et al. Effect of levodopa-carbidopa in­testinal gel on dyskinesia in advanced Parkinson's disease patients. Mov Disord. 2016;31:530-537.

66. Lang AE, Rodriguez RL, Boyd JT, et al. Integrated safety of levodopa- carbidopa intestinal gel from prospective clinical trials. Mov Disord. 2016;31:538-546.

67. Uncini A, Eleopra R, Onofrj M. Polyneuropathy associated with duode­nal infusion of levodopa in Parkinson's disease: features, pathogenesis and management. J Neurol Neurosurg Psychiatry. 2015;86:490-495.

68. Antonini A, Isaias IU, Rodolfi G, et al. A 5-year prospective assess­ment of advanced Parkinson disease patients treated with subcu­taneous apomorphine infusion or deep brain stimulation. J Neurol. 2011;258:579-585.

69. Manson AJ, Turner K, Lees AJ. Apomorphine monotherapy in the treatment of refractory motor complications of Parkinson's disease: long-term follow-up study of 64 patients. Mov Disord. 2002;17:1235-1241.

70. Katzenschlager R, Hughes A, Evans A, et al. Continuous subcutane­ous apomorphine therapy improves dyskinesias in Parkinson's dis­ease: a prospective study using single-dose challenges. Mov Disord. 2005;20:151-157.

71. Drapier S, Gillioz AS, Leray E, et al. Apomorphine infusion in advanced Parkinson's patients with subthalamic stimulation contraindications. Parkinsonism Relat Disord. 2012;18:40-44.

72. Drapier S, Eusebio A, Degos B, et al. Quality of life in Parkinson's dis­ease improved by apomorphine pump: the OPTIPUMP cohort study. J Neurol. 2016;263:1111-1119.

73. Borgemeester RW, Drent M, van Laar T. Motor and non-motor out­comes of continuous apomorphine infusion in 125 Parkinson's dis­ease patients. Parkinsonism Relat Disord. 2016;23:17-22.

74. Martinez-Martin P, Reddy P, Katzenschlager R, et al. EuroInf: a multi­center comparative observational study of apomorphine and levodopa infusion in Parkinson's disease. Mov Disord. 2015;30:510-516.

75. Volkmann J, Albanese A, Antonini A, et al. Selecting deep brain stim­ulation or infusion therapies in advanced Parkinson's disease: an evidence-based review. J Neurol. 2013;260:2701-2714.


76. Odin P, Nyholm D. Patient selection for continuous dopaminer­gic stimulation therapy. In: Aquilonius S-M, Mouradian MM, eds. Parkinson's Disease. Role of Continuous Dopaminergic Stimulation. Crowthorne: ESP Bioscience; 2012:162-172.